Today’s articles on Global Investing

Why Valeant Pharmaceuticals Is A Buy By George Kesarios • 61 comments It Is Time To Consider Vale By Orthodox Investor • 18 comments TransCanada: Straddle On Trump's Keystone XL Plan By Seeking Vol • 13 comments Australia Mesoblast Is Trying To Fool Investors Again By Alpha Exposure China Yuan Turbulence Bolsters China's Liberalisation Efforts by Global Risk Insights Denmark Novo Nordisk: Don't Be Fooled; This Stock Only Goes Up On Better-Than-Expected Results by Harm Elderman France Sanofi Q2 Results: Growth Of 2 Newly Launched Drugs, But Uncertainties Still Remain by Alexey Myasnikov Germany Central Bank Blundering Fixes Nothing by Kal Telage Japan Lost In Translation by Neuberger Berman Toyota: Traffic Ahead For Dividend Investors by Black Coral Research United Kingdom Early Macro News And Lessons From The Brexit by Econbrowser Canada Valeant: It's Neither Easy Nor Simple by Open Square Capital Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2016 Update by John Vincent Valeant's Pullback: Entry Point Or Falling Knife? by Chris Lau More Global Investing» Please do not forward this email. It allows direct access to your Seeking Alpha Portfolio. Why are you receiving this? You subscribed to Global Investing at Seeking Alpha. Unsubscribe from this email or manage all your Seeking Alpha email choices here. To ensure you receive these emails in the future, please add account@seekingalpha.com to your address book, contacts or list of safe senders. Sent by Seeking Alpha, 52 Vanderbilt Avenue, 13th floor, New York, NY 10017